H. Lundbeck 과거 수익 실적

과거 기준 확인 3/6

H. Lundbeck은 연평균 7%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 1.2%였습니다. 매출은 연평균 4.3%의 비율로 증가했습니다. H. Lundbeck의 자기자본이익률은 11.3%이고 순이익률은 12.5%입니다.

주요 정보

7.0%

수익 성장률

7.0%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	4.3%
자기자본 수익률	11.3%
순이익	12.5%
다음 실적 업데이트	05 Feb 2025

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

H. Lundbeck 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:HLBB.F 수익, 비용 및 수입 (DKK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	21,441	2,687	9,320	4,361
30 Jun 24	20,671	2,586	9,173	3,654
31 Mar 24	20,239	2,298	9,041	3,549
31 Dec 23	19,912	2,290	8,706	3,457
30 Sep 23	19,614	2,467	8,426	3,386
30 Jun 23	19,381	2,479	8,115	3,471
31 Mar 23	18,918	2,384	8,082	3,617
31 Dec 22	18,246	1,916	7,689	3,754
30 Sep 22	17,619	1,603	7,398	3,846
30 Jun 22	16,913	1,236	7,127	3,947
31 Mar 22	16,398	1,109	6,768	3,884
31 Dec 21	16,299	1,318	6,625	3,820
30 Sep 21	16,521	1,873	6,698	3,711
30 Jun 21	16,971	1,965	6,680	3,655
31 Mar 21	17,381	2,110	6,720	2,999
31 Dec 20	17,672	1,581	6,912	3,753
30 Sep 20	17,818	904	6,812	3,760
30 Jun 20	17,490	1,242	6,744	3,538
31 Mar 20	17,366	1,507	6,672	4,039
31 Dec 19	17,036	2,313	6,413	3,116
30 Sep 19	16,811	3,091	6,212	3,214
30 Jun 19	17,309	3,395	6,143	3,302
31 Mar 19	17,766	3,606	6,061	3,313
31 Dec 18	18,117	3,907	6,039	3,277
30 Sep 18	18,313	3,806	6,120	3,069
30 Jun 18	18,028	3,627	6,174	2,903
31 Mar 18	17,608	3,236	6,298	2,765
31 Dec 17	17,234	2,624	6,482	2,705
30 Sep 17	17,007	2,544	6,428	2,769
30 Jun 17	16,607	1,988	6,462	2,839
31 Mar 17	16,075	1,612	6,424	2,887
31 Dec 16	15,634	1,211	6,293	2,967
30 Sep 16	15,202	290	6,475	-1,979
30 Jun 16	14,923	-1,289	7,320	3,196
31 Mar 16	14,801	-5,427	7,573	3,095
31 Dec 15	14,594	-5,694	7,762	3,097
30 Sep 15	14,108	-5,879	7,814	8,003
30 Jun 15	13,625	-4,615	6,928	2,666
31 Mar 15	13,444	-565	6,581	2,790
31 Dec 14	13,468	-153	6,298	2,689
30 Sep 14	13,808	503	6,208	2,670
30 Jun 14	14,181	765	6,147	2,782
31 Mar 14	14,269	119	6,814	2,807
31 Dec 13	15,258	855	6,749	2,834

양질의 수익: HLBB.F 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: HLBB.F 의 현재 순이익 이익률 (12.5%) 작년보다 낮습니다 (12.6%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: HLBB.F 의 수입은 지난 5년 동안 매년 7% 씩 증가했습니다.

성장 가속화: 지난 1년간 HLBB.F 의 수익 증가율( 8.9% )은 연간 평균( 7% 초과합니다. ).

수익 대 산업: 지난 1년간 HLBB.F 수익 성장( 8.9% )은 Pharmaceuticals 업계 54.6% 능가하지 못했습니다. 54.6%.

자기자본 수익률

높은 ROE: HLBB.F 의 자본 수익률( 11.3% )은 낮음으로 간주됩니다.

H. Lundbeck 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기